Pay in 4 interest-free payments of $5.72 Learn more
Ships within 48 hours · Estimated delivery Aug 9 - Aug 14
Exposure to insulin is indicated to facilitate the removal of A in astrocytes through increased expression of IDE [150]
NEW YORK August 4, 2025 Noom, the leading digital healthcare company committed to chronic disease prevention and empowering people to live better longer, today announced the launch of the Noom Microdose GLP-1 Rx Program, a groundbreaking offering designed to unlock weight loss and long-term health benefits while minimizing side effects through personalized microdoses of GLP-1 medication, when clinically appropriate
GLP-1s may interact with insulin, other diabetes medications, or drugs used to treat depression and digestive or kidney diseases
Graphical abstract Access this article Similar content being viewed by others Data availability Data that support the findings of this study are available by the Lombardy Region, but restrictions apply to the availability of these data and codes, which were used under license for the current study, and so they are not publicly available
US$ 21.59
US$ 28.03
US$ 26.90
US$ 21.59
US$ 23.91
US$ 20.00
